Triple-negative Breast Cancer

Main Article Content

Panuwat Lertsithichai

Abstract

Triple-negative breast cancers are of current interest, and probably will be so in the near future. Therapeutically relevant subgroups of these cancers are increasingly being recognized, and therapies are being developed to deal with them. These novel therapies are not targeting triple-negative tumors uniquely, but rater targeting the more unfavorable subgroups. Some triple-negative cancers have very good prognosis if pathologically complete response can be obtained after chemotherapy. At the present time neoadjuvant chemotherapy provides a way to distinguish favorable from unfavorable subgroups.

Article Details

How to Cite
Lertsithichai, P. (2012). Triple-negative Breast Cancer. Ramathibodi Medical Journal, 35(1), 1–4. Retrieved from https://he02.tci-thaijo.org/index.php/ramajournal/article/view/117662
Section
Editor's Note

References

Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44(18):2799-805. doi:10.1016/j.ejca.2008.09.034.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48. doi:10.1056/NEJMra1001389.

Ray M, Polite BN. Triple-negative breast cancers: a view from 10,000 feet. Cancer J. 2010;16(1):17-22. doi:10.1097/PPO.0b013e3181d3eef5.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366(4):310-20. doi:10.1056/NEJMoa1111097.

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299-309. doi:10.1056/NEJMoa1111065.

Montero AJ, Vogel C. Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med. 2012;366(4):374-5. doi:10.1056/NEJMe1113368.

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-44. doi:10.1016/S0140-6736(10)60892-6.

O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 201;364(3):205-14. doi:10.1056/NEJMoa1011418.

Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008;14(5):456-63. doi:10.1111/j.1524-4741.2008.00622.x.

Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831-41. doi:10.1007/s10549-011-1891-6.